Results 41 to 50 of about 6,049 (169)

Health Care Use Among Patients Presenting to Emergency Department for Gout Flares in Ontario, Canada: A Population‐Based Health Systems Analysis

open access: yesArthritis Care &Research, EarlyView.
Objective We characterized emergency department (ED) gout visits and identified patient characteristics and health services patterns contributing to ED presentations. Methods We conducted a population‐based study of ED gout visits in Ontario, Canada, between 2014 and 2023.
Timothy S. H. Kwok   +7 more
wiley   +1 more source

Cardiovascular outcomes of febuxostat and allopurinol: A long-term Taiwanese nationwide cohort study

open access: yesJournal of the Formosan Medical Association
Introduction: Studies with larger cohorts and longer follow-up periods are required for cardiovascular safety of febuxostat and allopurinol. Material and methods: This population-based, retrospective study was conducted with the Taiwan National Health ...
Tsung-Lin Yang   +4 more
doaj   +1 more source

Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study

open access: yesScientific Reports, 2022
Attribute-based medicine is essential for patient-centered medicine. To date, the groups of patients with chronic kidney disease (CKD) requiring urate-lowering therapy are clinically unknown.
Hiroshi Kataoka   +10 more
doaj   +1 more source

Caregiver Perspectives on the Burden of Disease and Treatment in Uncontrolled Gout

open access: yesArthritis Care &Research, EarlyView.
Objective Uncontrolled gout (UG) refers to persistently elevated serum urate (SU) levels >6 mg/dL and ongoing gout symptoms despite use of urate‐lowering therapy (ULT). The objective of this study was to evaluate the burden associated with informal caregiving for individuals with UG.
Angelo Gaffo   +6 more
wiley   +1 more source

Febuxostat ameliorates EAE.

open access: yes, 2013
Febuxostat (0.75 mg/kg) or vehicle (water) was administered via water bottle from day 10 post-immunization until the end of the study. (A) Mean clinical scores of control mice (filled circle; n = 7) and febuxostat-treated mice (open square; n = 6) after ...
Hideki Mochizuki (204792)   +10 more
core   +1 more source

Photochemical Reaction Discovery Enabled by the Dynamic Speciation of Copper Complexes

open access: yesAngewandte Chemie, Volume 138, Issue 41, 5 October 2026.
A strategy for accelerated photochemical reaction discovery is reported that harnesses the dynamic speciation of copper complexes, driven by their labile metal–ligand bonds. This platform simplifies reaction screening by combining an earth‐abundant copper(II) salt with commercially available ligands, which reversibly generate multiple catalytic species
Alessio Regni   +6 more
wiley   +2 more sources

Switching from allopurinol to febuxostat: efficacy and safety in the treatment of hyperuricemia in renal transplant recipients

open access: yesRenal Failure, 2019
The aim of this study was to evaluate the efficacy and tolerability of febuxostat in renal transplant recipients who were previously treated with allopurinol (the daily oral dose is 100 mg).
Yanchun Li   +4 more
doaj   +1 more source

Nickel‐Catalyzed Three‐Component Difluoroalkylation‐Amination for the Direct Access to Anti‐Inflammatory β‐Difluoroalkyl Amines

open access: yesAdvanced Science, EarlyView.
A nickel‐catalyzed three‐component reductive fluoroalkylation‐amination strategy of N‐vinylamides for the direct access to the α‐amidyl‐β‐difluoroalkyl amines was reported here. The synthetic method features with broad substrate scope, mild conditions, high functional group tolerance, and convenience to handle.
Chang Xu   +8 more
wiley   +1 more source

Impact of febuxostat on visit-to-visit blood pressure variability: insights from the randomised PRIZE Study

open access: yesRMD Open, 2022
Objectives Although uric acid lowering therapies, including xanthine oxidase (XO) inhibition, may reduce the absolute level of blood pressure (BP), the effect of XO inhibition on BP variability is largely unknown.
Yoshio Kobayashi   +9 more
doaj   +1 more source

Pharmacokinetics and Bioequivalence of Two Formulations of Febuxostat 40-Mg and 80-Mg Tablets: A Randomized, Open-Label, 4-Way Crossover Study in Healthy Chinese Male Volunteers.

open access: yesPLoS ONE, 2016
UnlabelledThe present study aimed to investigate the pharmacokinetic properties of febuxostat in healthy Chinese male volunteers and evaluate whether the two formulations of febuxostat 40-mg and 80-mg tablets are bioequivalent.
Zhu Luo   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy